MedTrace Logo

An Open Label Study of IgG Fc Glycan Composition in Human Immunity

NCT01967238 · Status: TERMINATED · Phase: EARLY_PHASE1 · Type: INTERVENTIONAL · Enrollment: 129

Last updated 2024-09-19

Study results available
· View outcomes & findings →

Summary

In order to produce better more effective vaccines, it is important to understand the particulars of why individuals have an effective or ineffective immune response to vaccination. We are going to examine specific aspects of the antibody (IgG Fc glycan) made by healthy volunteers who receive different vaccines or who have a viral infection to understand the nature of an effective (or less effective) vaccine response. The results of this research could be used to develop adjuvants to increase/ improve vaccine response.

Conditions

  • Healthy

Interventions

BIOLOGICAL

IM Pneumococcal, meningococcal, or flu vaccine

Volunteers given one of the 3 vaccines

Sponsors & Collaborators

  • Rockefeller University

    lead OTHER

Principal Investigators

  • Taia T Wang, MD PhD · Rockefeller Univesrity

Study Design

Allocation
NON_RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2013-03-31
Primary Completion
2023-03-31
Completion
2023-03-31
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01967238 on ClinicalTrials.gov